Intellus Advisors LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Key Points

• Intellus Advisors LLC has acquired a new stake in Pfizer Inc. worth approximately $792,000, purchasing 31,247 shares in the 1st quarter.
• Pfizer reported an earnings per share (EPS) of $0.92 for the last quarter, exceeding analysts' expectations of $0.67, although revenue was down by 7.8% compared to the same quarter last year.
• The company has announced a quarterly dividend of $0.43 per share, representing an annualized yield of 6.94%, with a dividend payout ratio of 124.64%.

Intellus Advisors LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 31,247 shares of the biopharmaceutical company's stock, valued at approximately $792,000.

A number of other large investors have also bought and sold shares of PFE. Pacer Advisors Inc. increased its position in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Starboard Value LP acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $407,730,000. Assenagon Asset Management S.A. lifted its position in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. grew its stake in shares of Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after buying an additional 5,153,257 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PFE. Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Redburn Atlantic dropped their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Stock Down 1.9%

PFE stock traded down $0.46 during trading on Monday, reaching $24.33. The stock had a trading volume of 31,036,641 shares, compared to its average volume of 45,350,316. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $24.30 and its two-hundred day moving average is $24.65. The company has a market capitalization of $138.33 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm earned $0.82 EPS. The company's revenue was down 7.8% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.07%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.